$10.9B Acquisition: AbbVie Buys Apogee, Clarifies Lead Drug Phase 3 Timeline
APGE has more than doubled off its 52-week low of $34.34 on elevated volume (32× avg).
Summary
AbbVie has entered a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the deal at approximately $10.9 billion. This follows yesterday's SEC filings confirming the acquisition. The news also clarifies that Apogee's lead drug, zumilokibart, is expected to enter Phase 3 later this year, correcting earlier reports that it was already in Phase 3. This acquisition provides a substantial premium for Apogee shareholders, and the updated drug development timeline is a critical detail for assessing the value of the pipeline.
At the time of this announcement, APGE was trading at $132.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $34.34 to $133.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.